文献速递糖尿病

替尔泊肽治疗GADA阳性者改善HbA1c和体重:SURPASS事后分析

Improved HbA1c and Body Weight in GADA-Positive Individuals Treated With Tirzepatide: A Post Hoc Analysis of SURPASS.
PubMed 文献 · J Clin Endocrinol Metab · 2025-01-01

基于SURPASS 2-5汇总数据的的事后分析纳入3791例临床诊断2型糖尿病者,比较替尔泊肽(5、10、15 mg)治疗40/42周时GADA阳性与阴性者的HbA1c和体重变化。两组HbA1c和体重均大幅下降,GADA阴性者HbA1c降幅更大(估计差异0.21% [95%CI 0.03, 0.39];P=.024),体重降幅组间无差异(0.38 kg [-0.99, 1.75];P=.588)。

要点

  • 替尔泊肽治疗40/42周,GADA阳性与阴性者HbA1c和体重均大幅下降(P<.001)。
  • GADA阴性者HbA1c降幅大于阳性者,估计差异0.21%(95%CI 0.03, 0.39;P=.024)。
  • 体重降幅两组间无显著差异,估计差异0.38 kg(95%CI -0.99, 1.75;P=.588)。

核心结论

  • 在临床诊断2型糖尿病的成人中,替尔泊肽与HbA1c和体重的大幅降低相关,且不受GADA状态影响,提示替尔泊肽可能改善LADA患者的血糖控制。

研究设计与样本

  • 基于SURPASS 2-5汇总数据的事后分析,纳入3791例临床诊断2型糖尿病者,采用混合模型重复测量,校正研究及基线协变量(年龄、性别、基线值、BMI和GADA状态)。
  • 干预为替尔泊肽5、10、15 mg;主要结局为第40周(SURPASS-2、-3、-5)和第42周(SURPASS-4)HbA1c较基线的变化,按GADA状态分层。

主要发现

  • 在GADA状态确认的参与者中,3671例(96.8%)为GADA阴性,120例(3.2%)为GADA阳性(其中76例[63.3%]为低水平,44例[36.7%]为高水平)。
  • 基线特征组间相似,唯GADA阳性者BMI略低于GADA阴性者(平均[SD] BMI 32.2 [6.1] vs 33.6 [6.3])。
  • 第40/42周,两组HbA1c分别降低-2.11% vs -2.32%,体重分别降低-9.2 kg vs -9.6 kg(两组P<.001)。
  • GADA阴性者HbA1c降幅更大(估计差异[95%CI]:0.21% [0.03, 0.39];P=.024),体重降幅组间无差异(0.38 kg [-0.99, 1.75];P=.588)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

CONTEXT: People with clinically diagnosed type 2 diabetes (T2D) but positive antiglutamic acid decarboxylase autoantibodies (GADA), referred to here as latent autoimmune diabetes in adults (LADA), may experience more rapid glycemic deterioration than those with T2D and may benefit from effective diabetes treatment with additional metabolic benefits. OBJECTIVE: This work aimed to assess glycated hemoglobin A1c (HbA1c) and body weight (BW) changes associated with tirzepatide in GADA-positive vs GADA-negative participants with a clinical T2D diagnosis. METHODS: Post hoc analyses based on pooled data from SURPASS 2-5, using mixed-model repeated measures from the efficacy analysis set, adjusting for study and baseline covariates including age, sex, baseline values, body mass index (BMI), and GADA status, were conducted on 3791 individuals. Intervention included tirzepatide (5, 10, 15 mg). Main outcome measure included change from baseline in HbA1c at weeks 40 (SURPASS-2, -3, -5) and 42 (SURPASS-4) by GADA status. RESULTS: In participants with confirmed GADA status, 3671 (96.8%) were GADA negative and 120 (3.2%) were GADA positive (76 [63.3%] with low and 44 [36.7%] with high GADA levels). Baseline characteristics were similar between groups, except for slightly lower BMI in GADA-positive vs GADA-negative participants (mean [SD] BMI 32.2 [6.1] vs 33.6 [6.3]). At week 40/42, both groups achieved robust reductions in HbA1c (-2.11% vs -2.32%) and BW (-9.2 kg vs -9.6 kg) (P < .001, both groups). HbA1c reductions were greater in GADA-negative participants (estimated difference [95% CI]: 0.21% [0.03, 0.39]; P = .024) and BW reductions did not differ between groups (0.38 kg [-0.99, 1.75]; P = .588). CONCLUSION: In this post hoc analysis, tirzepatide was associated with substantial reductions in HbA1c and BW irrespective of GADA status in adults diagnosed with T2D, suggesting that tirzepatide may improve glycemic control in individuals with LADA.

来源:J Clin Endocrinol Metab,查看原文。版权归原作者所有。

引用

  1. Peters AL, Buzzetti R, Lee CJ, et al. Improved HbA1c and Body Weight in GADA-Positive Individuals Treated With Tirzepatide: A Post Hoc Analysis of SURPASS. J Clin Endocrinol Metab. 2025. PMID: 38824910. doi:10.1210/clinem/dgae372

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。